REGISTER
Everest Medicines’ Etrasimod Approved for Launch
Everest Medicines has secured Chinese approval for etrasimod in adults with moderately to severely active ulcerative colitis who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics, supported by both Asian and global Phase III data.

On February 6, Everest Medicines announced that the NMPA had approved etrasimod for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or intolerance to conventional therapy or biologics.

Etrasimod (VELSIPITY, formerly known as etrasimod) is a once-daily oral, next-generation, highly selective sphingosine-1-phosphate (S1P) receptor modulator. With optimized pharmacologic design, it binds S1P receptors 1, 4, and 5 while sparing subtypes 2 and 3, providing both systemic and local cellular modulation with rapid onset and rapid T-lymphocyte recovery.

As a blockbuster product in Everest Medicines’ autoimmune disease portfolio, etrasimod can strongly promote intestinal mucosal healing, is convenient to use, and has a favorable safety profile. It has already been approved in the United States, the European Union, Canada, Japan, Australia, the United Kingdom, Switzerland, Israel, Macao SAR, Singapore, and Hong Kong SAR.

This approval was based on the Asian multicenter Phase III registrational ENLIGHT UC study (ES101002) and the global Phase III registrational ELEVATE UC studies, including ELEVATE UC 52 and ELEVATE UC 12.

ENLIGHT UC is the largest completed Phase III registrational study in Asian patients with moderate to severe active ulcerative colitis, enrolling a total of 340 patients. During the 12-week induction phase and 40-week maintenance phase, the Velsipity treatment group achieved statistical significance and clinical relevance across all primary and secondary efficacy endpoints and showed good safety. ELEVATE UC 52 and ELEVATE UC 12 were randomized, double-blind, placebo-controlled trials that also met all primary and key secondary endpoints, with a safety profile consistent with previous studies.

The Asian multicenter ENLIGHT UC Phase III study showed that after 40 weeks of maintenance treatment, the clinical remission rate with Velsipity was 48.1%, the mucosal healing rate was 51.9%, and the endoscopic normalization rate was 45.5%, with good safety and tolerability.

According to full maintenance-phase data released at ECCO 2025, the proportion of patients achieving clinical remission at Week 40 was significantly higher with etrasimod than with placebo at 48.1% versus 12.5% (treatment difference 35.9% [95% CI: 22.5%, 49.2%], two-sided p<0.0001), representing a marked clinical benefit.

All key secondary endpoints also showed clinically and statistically significant improvement, including endoscopic improvement at Week 40 (61.0% vs 15.0%; percentage difference 46.6% [95% CI: 33.2%, 60.1%], p<0.0001) and clinical response (79.2% vs 35.0%; percentage difference 45.6% [95% CI: 31.9%, 59.3%]).

Other secondary endpoints, including mucosal healing and endoscopic normalization, also reached clinically and statistically significant improvement (p<0.0001). For example, 51.9% of etrasimod-treated patients achieved mucosal healing, defined as central-read endoscopic subscore ≤1 excluding friability and Geboes score <2.0, versus only 8.8% in the placebo group.

Maintenance treatment showed good safety for etrasimod, and safety data were consistent with the known profile, with no new safety signals observed.

In addition, at the 13th Annual Meeting of the Asian Organization for Crohn’s and Colitis in July 2025, Everest Medicines presented global four-year safety results for etrasimod, covering 1,196 UC patients and 1,619.5 patient-years of follow-up, with the longest treatment follow-up reaching about four years (208.9 weeks), again supporting its tolerability and safety with strong clinical evidence.

Ulcerative colitis is an inflammatory bowel disease characterized by symptoms including chronic diarrhea with blood and mucus, abdominal pain and cramping, and weight loss, with major impact on patients’ work and daily life. Existing therapies each have limitations, which continues to drive active research into drugs targeting new inflammation-related pathways.

Compared with other novel therapies, S1P receptor modulators do not carry a boxed safety warning and also offer the convenience of oral dosing, which has helped spur active dealmaking.

Insight database shows that Everest Medicines identified the value of etrasimod as early as 2017, licensing the asset from Arena while it was still in Phase II for an upfront payment of USD 12 million plus milestones of USD 212 million.

In March 2022, Pfizer acquired Arena for USD 6.7 billion to gain this blockbuster pipeline asset. Pfizer believes the drug may become best in class, redefine first-line treatment standards, and achieve peak sales of USD 1 billion to USD 2 billion.

Everest Medicines first achieved annual commercialization profitability in 2024, supported by a broad pipeline across kidney disease, anti-infectives, and autoimmune disease, covering short-, mid-, and long-term opportunities. This NMPA approval of etrasimod will add further momentum to the company.

0
0
Loading